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Opioids play an important role for the management of acute pain and in palliative care. The role of long-
term opioid therapy in chronic non-malignant pain remains unclear and is the focus of much clinical
research. There are concerns regarding analgesic tolerance, paradoxical pain and issues with dependence
that can occur with chronic opioid use in the susceptible patient. In this review, we discuss how far
human neuroimaging research has come in providing a mechanistic understanding of pain relief pro-
vided by opioids, and suggest avenues for further studies that are relevant to the management of chronic
pain with opioids.
This article is part of the Special Issue Section entitled ‘Neuroimaging in Neuropharmacology’.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Basic science has advanced our understanding of nociception
and suggests numerous receptors that can be targeted by drugs for
pain relief in humans. Unfortunately, few novel compounds have
emerged as clinically useful analgesics (Mogil, 2009). Opioids are
themainstay for themanagement of acute pain (Wu and Raja, 2011)
and in palliative care (Portenoy, 2011), where the duration of
treatment is limited.
The role of opioids for the treatment of chronic non-malignant
pain remains debatable (Chou et al., 2009a). Chronic pain, by
deﬁnition, persists beyond 3 months. In many patients, the ﬂuc-
tuations in the severity of such pain are not clearly correlated with
demonstrable changes in a peripheral or central disease process.
There are concerns that opioid-based medications may fail to
maintain their efﬁcacy when used indeﬁnitely to relieve such pain.
Robust data on opioid treatment efﬁcacy in these patients are
lacking (Noble et al., 2010), and concerns have grown over the
escalating death rates from prescription-opioid overdose reported
in the United States (Okie, 2010). Nonetheless, there is still generaldcliffe Hospital, Headington,
22 724, þ44 1865 222 736;
(M.C. Lee), irene.tracey@
Published by Elsevier Ltd. This is aconsensus amongst clinicians, that long-term management of pain
with opiates can be beneﬁcial, or at least safe with appropriate
patient selection and dose titration (British Pain Society, 2010;
Chou et al., 2009b; Kahan et al., 2011a, 2011b).
Opioid receptors are distributed throughout the nervous sys-
tem. Experimental studies have demonstrated analgesic effects via
stimulation of opioid receptors that are peripheral or centrally
located (Dickenson and Kieffer, 2013). There are key spinal and
supraspinal actions of opioids and the latter involves descending
pathways. Furthermore, recent clinical trials with methyl-
naltrexone, a peripherally restricted mu-opioid-receptor antago-
nist, suggest that the effects within the central nervous system are
important to pain relief afforded by systemic delivery of opioids in
palliative care and chronic non-malignant pain (Anissian et al.,
2012; Michna et al., 2011; Thomas et al., 2008). Thus, human
brain neuroimaging studies may further our understanding of the
central processes through which opiates operate to provide pain
relief.
Most human neuroimaging research in humans is focussed on
the acute effects of opioids on experimentally induced pain in
humans. Far less is known about the effects of chronic opioid
analgesic therapy on the central nervous system in humans. Anal-
gesic tolerance is a long-held limitation of chronic opioid therapy.
More recent data now suggests that chronic opioid administration
or withdrawal cause a hyperalgesic state (Bannister and Dickenson,
2010) where opioids can paradoxically worsen pain. Furthermore,n open access article under the CC BY-NC-ND license (http://creativecommons.org/
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and medication misuse, particularly in the vulnerable (Pergolizzi
et al., 2012).
Here, we discuss how far human neuroimaging research has
come in translating mechanistic data from other species, suggest
avenues for further studies that are relevant to the long-term
management of pain with opioids.
2. Neuroimaging opioid-based analgesia
2.1. Acute administration of opioids
Neuroimaging research suggests that the experience of pain
emerges from an extensive network of brain regions (Apkarian
et al., 2005), which is unsurprising given how complex pain really
is (Tracey, 2005). The International Association for the Study of Pain
(IASP) deﬁnes pain as ‘an unpleasant sensory or emotional expe-
rience associated with actual or potential tissue damage, or
described in terms of such damage’ (IASP, 1994). This deﬁnition is
based on the concept of pain as a speciﬁc consciousness comprising
of sensory, emotional and cognitive aspects. Brain imaging has
provided evidence for neural mechanisms that contribute to pain
perception and its modulation, but the neuro-signature of pain it-
self remains elusive (Tracey and Mantyh, 2007).
Nearly all neuroimaging studies of opioid analgesia have been
performed in healthy volunteers, in whom the effects of opioids on
pain from brief non-injurious noxious stimuli are examined (Adler
et al., 1997; Oertel et al., 2008; Petrovic et al., 2002; Wagner et al.,
2007; Wise et al., 2002). Experimentally induced pain cannot
replicate the distress experienced by patients with long-term pain
that is often difﬁcult to treat. Nonetheless, studies in healthy vol-
unteers allow for more precise stimulation of the nociceptive sys-
tem and pharmacological modulation of the resultant experience of
pain without illness, disease and treatment confounds. In these
highly controlled experiments, short-acting intravenous opioids,
for example remifentanil or alfentanil, are often employed to
minimise variability from pharmacokinetics between individual
subjects.
The early pharmacodynamic FMRI studies from our laboratory
revealed that opioids decrease pain-related activations in a spe-
ciﬁc and dose dependent manner (Wise et al., 2002, 2004). Acti-
vations within the intra-calcarine cortex that are related to visual
stimulation, a control task employed in these experiments, were
not signiﬁcantly affected by opioid administration. This ﬁnding
suggests that the suppression of sensory-limbic activations was
related to speciﬁc effects on neural processing, rather than global
vascular effects from hypercarbia related to hypoventilation dur-
ing opioid analgesia (Wise and Tracey, 2006). Furthermore, an
investigation of the acute effects of remifentanil on FMRI activa-
tions after controlling for hypercarbia have not revealed direct
effects of remifentanil on cerebral vascular reactivity itself
(Pattinson et al., 2007). Interestingly, we found that activations
evoked within the insular regions by noxious stimuli were
particularly susceptible to remifentanil (Wise et al., 2002, 2004).
The data are consisted with the known role of insular cortex in
nociception and pain perception (Craig, 2003; Mazzola et al.,
2009; Ostrowsky et al., 2002).
Oertel et al. (2008) have further demonstrated that opioid
analgesic dose response functions differ between the posterior and
anterior insula cortex. In their study, the posterior insula and other
regions that encode the sensory aspects of pain, also demonstrate a
linear reduction of activity with increasing intravenous opioids
dose. However, they report that activations in the amygdala,
anterior insula and cingulate cortices, which are regions implicated
in the affective aspects of pain (Craig, 2009), are maximallysuppressed at the lowest opioid dose. Their ﬁndings suggest that
the limbic regions are exquisitely sensitive to opioid effects,
consistent perhaps with their high opioid receptor densities (Fig. 1).
The subjects only reported on the sensory aspects of pain in that
study. Nonetheless, the FMRI data suggest that opioid analgesics
can directly inﬂuence emotional responses at low doses that do not
alter sensory aspects of pain (Fig. 2).
Opioid analgesia is not exclusively associated with suppression
of brain activity. Wagner and colleagues found increased activation
in the perigenual anterior cingulate cortex (ACC) and the peri-
aqueductal grey (PAG) activations during opioid analgesia (Wagner
et al., 2007). Converging evidence suggests that these regions
comprise the neural circuit for the descending modulation of
nociception, which include frontal-limbic and brainstem regions
(Tracey, 2010). Baseline ﬂuctuations of activity within regions in
this circuit can predict moment-to-moment variation in the
threshold of pain sensation within individuals, and relates to
differences in trait anxiety and pain vigilance between
individuals (Ploner et al., 2010). Endogenous opioids are known to
contribute to the function of this descending neural circuit
(Bencherif et al., 2002; Sprenger et al., 2006; Zubieta et al., 2001).
Opioids can activate this same neural circuit for analgesic effects
(Petrovic et al., 2002), which is shown to be active across FMRI
studies during noxious stimulation itself (Fig. 2).
Interestingly, pain from noxious stimulation is also associated
with activations in the several brain regions that are better known
for their roles in processing rewards, such as monetary gain,
palatable food, drugs and pleasurable social interactions (Becerra
et al., 2001). These regions include the orbitofrontal cortex (OFC),
nucleus accumbens (NA) and the ventral tegmental area (VTA), all
of which are densely populated by opioid receptors. FMRI activa-
tions of these ‘reward’ regions during noxious stimulation may
reﬂect increased endogenous opioidergic transmission for the
regulation of pain. This increased opioidergic tone has been
considered an opponent-process (pain-opposing) that persists
brieﬂy after cessation of the noxious stimulation to explain the
experience of relief (from pain) (Leknes and Tracey, 2008; Seymour
et al., 2005). Supporting the opponent-theory of pain are studies
from our group and others studies demonstrating increased acti-
vations in similar reward regions when pain relief is experienced
from the cessation or diminution of noxious stimulation (Baliki
et al., 2010; Leknes et al., 2011). More recently, we demonstrated
that pain relief related to opioids could be predicted from the
baseline reactivity of ‘reward-regions’ within the brain in an FMRI
study (Wanigasekera et al., 2012). In that study, activations within
the OFC, NA and VTA evoked by painful noxious stimulation prior to
opioid administration were positively correlated to reductions in
subjective reports of pain intensity from identical noxious stimu-
lation during opioid administration in healthy individuals. Opioid
analgesia was also positively correlated with a psychometric mea-
sure of reward responsiveness, though neuroimaging data better
accounted for the variance in opioid effects on pain ratings.
Together these data suggest that opioid analgesia also involves
neural mechanisms for reward processing. Interestingly, activity in
these ‘reward regions’ evoked by noxious stimulation during opioid
administration did not correlate with analgesic effect, suggesting
that exogenous opioids do not directly modulate these reward re-
gions for analgesic effect but may operate on shared mechanisms
that are further downstream. For example, the baseline reactivity of
the VTA also signiﬁcantly predicted the opioid-induced changes in
neuronal activity in the right amygdala and the left hippocampus,
which may in turn inﬂuence the expression of behavioural anal-
gesia in the study.
As with any treatment for pain, opioid analgesia can be inﬂu-
enced by the belief (expectancy) of efﬁcacy held by the individual.
Fig. 1. Opioid receptor distribution in the human brain. [Above] The distribution of opiate receptors in the medial and lateral aspects of brain is revealed by an in-vivo study of
opiate binding potential using radiolabeled carfentanil, a mu-opiate receptor ligand. There is increased binding in the frontal-limbic relative to sensory regions (Rabiner et al., 2011).
[Below] Axial sections showing the gross anatomy (left) and radio-ligand binding to mu opiate receptors. Note the high opioid receptor densities in the insular region (Martin et al.,
2007). Courtesy of Professor Bruce Morton.
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substantiated by neuroimaging research as a genuine psychobio-
logical event. Endogenous opioids are known to contribute to pla-
cebo effect (Scott et al., 2008; Wager et al., 2007). Opioidergic
mechanisms for placebo analgesia operate within the neural circuit
for the descending control of pain, including the ACC, the PAG and
the spinal dorsal horn (Eippert et al., 2009). More recently, we
investigated whether effects from positive and negative expec-
tancies of opioid analgesia engaged similar brain regions in healthy
subjects (Bingel et al., 2011). The experiment involved a ﬁxed and
constant infusion of remifentanil. Subjects reported slightly lower
pain compared to baseline when the infusion commenced but
knowledge of that was hidden. Pain relief became signiﬁcantly
superior when subjects were told that the infusion had
commenced. When informed that the infusion had ceased (though
in reality the infusionwas continued), their ratings of pain returned
to baseline. The FMRI data revealed that effects of positive and
negative expectancies on opioid analgesia involve distinct neuro-
anatomical substrates. Expectation of poor analgesic effect was
accompanied by activation of the entorhinal cortex, a hippocampal
region that mediates the exacerbation of pain through anxiety,
through inhibition of perigenual ACC activity (Ploghaus et al.,
2001). Conversely, positive expectation of analgesic effect was
associatedwith increased perigenual ACC activation, suggesting the
descending mechanisms of pain inhibition were engaged.
In addition to the areas described above that were expectancy
‘speciﬁc’, activations within the primary somatosensory, insular
and mid-anterior cingulate cortices regions followed subjective
reports of pain that was modulated by expectancy under a ﬁxedremifentanil dose. It should be noted, though, that activations in
those regions did not return to baseline levels during the nocebo
arm unlike the subjectively reporting pain ratings. Hence, they
reﬂect the true pharmacodynamic action that occurred and illus-
trate nicely the value of imaging that is not a simple surrogate
marker of pain rating slavishly following the subjective report but
are something additional. However, activations in many of these
same somatosensory, insular and cingulate regions also correlate
with pain modulated by varying doses of remifentanil without
psychological manipulation (Wise et al., 2002, 2004). This raises
the question about whether placebo and intrinsic opioid effects
might interact signiﬁcantly to impact estimates of drug effective-
ness in placebo-controlled clinical trials, where a brain ‘on drug’
might not be able tomount the same placebo effect andmechanism
as a brain ‘off drug’.
Atlas et al. (2012) employed a full factorial experimental design
in their recent study to investigate potential interaction effects
between remifentanil and expectation on pain ratings as well as
brain activity. They did not ﬁnd signiﬁcant interaction effects on
pain ratings, or brain activity. Pain relief from remifentanil and
expectation were indistinguishable based on subjective pain rat-
ings. FMRI did not reveal regions where interaction effects were
signiﬁcant. Instead, expectancy and remifentanil effects were
distinguishable because they inﬂuenced different brain regions.
Additionally, expectancy and remifentanil effects had different
onsets. Expectancy effects occurred soon after the subjects became
aware the infusion had started, whereas remifentanil effects
become prominent only after peak blood concentrations were
achieved from the infusion. These studies on drug and expectancy
Fig. 2. Brain mechanisms of opioid analgesia. Pain perception is generated by neural
activation in the inter-connected (light-grey arrows) brain regions that have sensory-
discriminatory (blue) and affective-motivational (red) functions. Opioids may alter the
consciousness of pain directly by preferential targeting of limbic regions (in red box).
Additionally, opioids may engage limbic-brainstem inhibition of spinal nociception
(dark grey arrows), which also occurs during cognitive control of pain that involves the
prefrontal cortex (PFC).
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neuro-anatomies. Further research is needed to explore the possi-
bility of isolating the contribution of placebo or nocebo effects on
pain based on neuroimaging data during clinical drug trials.
2.2. Opioid receptor availability e PET studies
Neuroimaging studies on the effects of opioids are scant in pa-
tients with chronic non-malignant pain. However, central effects
appear critical to opioid analgesia in humans. Hence data regarding
the distribution of opioid-receptors in the brain in patient pop-
ulations can be instructive (Fig. 1).
Patients with chronic non-malignant pain are a heterogeneous
group. Clinical trials have not revealed any particular clinical pain
syndrome for which opioids are particularly efﬁcacious. The earliest
PET study suggests that opioid-receptor binding is decreased dur-
ing a period of increased pain related to inﬂammation in a small
group of patients with rheumatoid arthritis (Jones et al., 1994). An
interpretation for the decreased opioid-receptor binding observed
in the longitudinal study is increased occupancy by release of brain
endorphins; possibly centrally regulated pain caused by the joint
inﬂammation.
Other investigators have employed caseecontrol designs in
their PET studies of individuals with well-characterized neuro-
pathic pain. In general, they demonstrate decreased opioid-
receptor binding in patients compared to age-matched healthy
controls (Jones et al., 2004; Maarrawi et al., 2007; Willoch et al.,
2004). Complex regional pain syndrome (CRPS) and ﬁbromyalgia
are currently diagnoses of exclusion: the contributing pathologies
remain unclear in symptomatic individuals. In these pain syn-
dromes, opioid-receptor binding is again altered primarily in the
frontal and limbic regions, and further accounts in part for the
variance observed in the self-reports of affect and mood related to
pain in patients (Harris et al., 2007; Klega et al., 2010).
A reduced opioid-receptor density has been proposed as an
explanation for the efﬁcacy of exogenous opioids or the lack thereofin patients (Harris et al., 2007; Maarrawi et al., 2007). However,
binding potential is an estimate of available receptors, which de-
pends on the afﬁnity and selectivity of ligand (Henriksen and
Willoch, 2008). A change in binding potentials may be related to
receptor occupancy by endogenous opioid peptides or change in
absolute quantity of receptors. Additionally, the action of different
opioids varies depending on the selectivity of their binding to
opioid-receptor subtypes (Melichar et al., 2005).
3. Opioid tolerance and drug-induced hyperalgesia
3.1. Analgesic tolerance
Opioid-induced tolerance is simply described as a shift to the
right in the doseeresponse curve: a higher dose is required over
time to maintain analgesic effect. Progressive disease may lead to
higher opioid requirements. Tolerance also results from pharma-
cokinetic change, for example, when the drug up-regulates the
activity of a metabolic process that facilitates its elimination from
the body. For this review, “opioid tolerance” refers to pharmaco-
dynamic tolerance, which reﬂects drug-activated changes in the
response of the neural systems.
Mechanisms for analgesic tolerance include altered molecular
signalling pathways and down-regulation of opioid receptors (Nagi
and Pineyro, 2011). These mechanisms are largely elucidated in
healthy animal models. Data regarding opioid tolerance in animal
models of inﬂammation, injury and disease are few and inconsis-
tent. Some behavioural studies suggest that tolerance to the anti-
nociceptive effects (withdrawal effects) of opioids develop more
slowly in inﬂammatory (Vaccarino et al., 1993; Zollner et al., 2008),
cancer (Urch et al., 2005) and neuropathic models (Iwai et al., 2012)
when compared to sham controls. Other studies demonstrate
enhanced development of analgesic tolerance, particularly in
neuropathic models (Raghavendra et al., 2002). The inconsistencies
appear related to the species, disease model and the opioid and
dose administered (Mogil, 2009).
3.2. Opioid-induced hyperalgesia
Distinct from tolerance, the excitatory effects of opioids at the
cellular level are thought to cause opioid-induced hyperalgesia
(Muscoli et al., 2010; Simonnet and Rivat, 2003; van Dorp et al.,
2009; Waxman et al., 2009). In clinical practice, opioid-induced
hyperalgesia is diagnosed when generalised pain develops and
worsens with escalating opioid dose (Tompkins and Campbell,
2011). Improvement following opioid dose reduction is recom-
mended to help distinguish between opioid tolerance and excit-
atory effects (Baron and McDonald, 2006). However, discomfort
related to drug withdrawal can negatively inﬂuence the overall
pain experienced and cloud the diagnosis.
Opioid-induced hyperalgesia is mainly demonstrated after
prolonged administration of opioids in healthy animal models
(Bannister and Dickenson, 2010; Heinl et al., 2011). These data
appear consistent with ﬁndings of decreased tolerance of noxious
stimuli in human individuals maintained on long-term metha-
done to manage opioid dependence (Compton et al., 2000;
Doverty et al., 2001; Pud et al., 2006). However, a recent study
in which oxycodone was administered orally over days in
healthy volunteers without a history of drug misuse revealed no
analgesic tolerance or hyperalgesia (Cooper et al., 2012). Hence,
the development of tolerance or hyperalgesia may vary with the
duration of administration, dose and opioid chemistry (Angst and
Clark, 2006).
Susceptibility to these hyperalgesic drug effects may also differ
between individuals. In healthy volunteers, cessation of
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et al., 2009; Luginbuhl et al., 2003; Wanigasekera et al., 2011) or
enhance hyperalgesia (Angst et al., 2003; Petersen et al., 2001)
but not consistently. The phenomenon of opioid post-infusion
hyperalgesia has been investigated recently in a combined
psychophysical-fMRI study (Wanigasekera et al., 2011). Only half of
all subjects recruited developed post-infusion hyperalgesia to
noxious thermal stimuli, implying considerable inter-individual
variation for the phenomenon, possibly related to genetic suscep-
tibility (Jensen et al., 2009). Midbrain reticular formation activation
was signiﬁcantly increased only in hyperalgesic subjects but
correlated negatively with the degree of hyperalgesia, which sug-
gest that brainstem activity regulates, rather than drives sensiti-
sation effects during opioid withdrawal.
In that human FMRI study (Wanigasekera et al., 2011), subjects
who developed opioid post-infusion hyperalgesia were indistin-
guishable from the rest of study cohort during the remifentanil
infusion itself: decreases in subjective ratings of pain during opioid
infusion were similar in both groups. In subjects who subsequently
developed post-infusion hyperalgesia, FMRI revealed increased
activation in the midbrain reticular formation during the opioid
infusion, suggesting initiation of pro-nociceptive process in that
brief period. This was an acute administration studywith an hour of
opioid infusion, it remains unclear whether opioid-induced
hyperalgesia would have occurred eventually had the infusion
been prolonged in the susceptible individuals.
3.3. Opioid-induced hyperalgesia in injury or disease
In contrast to opioid-induced hyperalgesia in healthy animals,
relatively few animal studies demonstrate opioid-induced hyper-
algesia in the presence of tissue injury (Celerier et al., 2006; Li et al.,
2001; Liang et al., 2008), inﬂammation (Rivat et al., 2009) or cancer
(King et al., 2007), suggesting that these pathological states are
protective. Notably, the doses of opioids used to induce hyper-
algesia appear higher than those employed to study opioid
tolerance.
Several clinical investigators have reported increased post-
surgical pain scores and analgesic requirements following intra-
operative remifentanil administration (Guignard et al., 2000; Rauf
et al., 2005). However, the effects are small and are not repro-
duced in other comparable studies (Cortinez et al., 2001; Lee et al.,
2005), leading to questions about the relevance of opioid tolerance
or withdrawal-induced hyperalgesia in peri-operative pain man-
agement (Fishbain et al., 2009). Quantitative sensory testing in
patients whose pain is managed by chronic opioid therapy reveals
decreased pain thresholds to noxious stimuli during opioid therapy
(Chen et al., 2009; Chu et al., 2006) but not consistently (Reznikov
et al., 2005). Again, the ﬁndings are difﬁcult to interpret, as the
patients were heterogeneous in terms of pain phenotypes. Also, the
relevance of QST ﬁndings to the clinical pain state is yet to be fully
established.
4. Pain and opioid addiction
4.1. Opioid self-administration
In laboratory settings, unrestrained and healthy rats exposed to
morphine by chance will subsequently self-administer opiates
regularly (Gardner, 2000). This behavioural model has long been
employed as a tool for studying neurobiology of addiction (Weeks,
1962). There are less data on how inﬂammatory or neuropathic
pain might modulate volitional opioid self-administration. Rats
with experimental arthritis increase opioid self-administration
with progression of inﬂammation. Opioid self-administrationdecreased with alleviation of inﬂammation by indomethacin or
dexamethasone treatment (Colpaert et al., 1982, 2001; Lyness et al.,
1989). Also, opiates do not seem to act as reinforcers in neuropathic
models of pain (Ozaki et al., 2003, 2004). Sustained activation of the
kappa-opioidergic system within the nucleus accumbens is
observed in the inﬂammatory pain state, and is thought to suppress
drug-rewarding effects (Narita et al., 2005).
More recently, Ewan and colleagues compared the effects of
morphine and cocaine on intracranial electrical self-stimulation
(ICSS) of the VTA in the nerve-ligated rat, a model of neuropathic
pain (Ewan andMartin, 2011). ICSS is an operant paradigm inwhich
rats will press a lever repeatedly in order to receive intracranial
electrical stimulation, which is highly rewarding by itself. In
healthy rats, cocaine and opioids facilitated ICSS. In contrast,
cocaine facilitated ICSS in nerve-ligated rats but opioids, which
produced analgesic effects, did not. A subsequent experiment by
the same investigators revealed opposite effects of these drugs on
ICSS of the paraventricular nucleus (PVN) of the hypothalamus:
opioids facilitate ICSS to a greater extent than cocaine (Ewan and
Martin, 2012). Their studies reveal the complex interaction be-
tween opioid analgesia and reward-seeking behaviour. The rein-
forcing properties of opioids are modulated by neuropathic pain
and appear to be mediated differently from those of cocaine, a
clearly non-analgesic but addictive drug.
Overall, the experimental data suggest that opioids do not act as
primary reinforcers in the presence of pain that is clearly attrib-
utable to peripheral or central pathology. This is consistent with the
bulk of clinical experience of opioid use for post-surgical (Wu and
Raja, 2011), and cancer-related pain (Portenoy, 2011).
4.2. Subjective effects of opioids
The positive subjective effects induced by opioids are thought to
be reinforcing in humans but there is evidence that pain modulates
these effects. In healthy subjects without clinical pain or history of
recreational drug dependence, positive subjective effects of opioids
are decreased during pain caused by hand-immersion in icy-cold
water (Conley et al., 1997; Zacny et al., 1996). The subjective ef-
fects of opioids may differ in the presence of chronic pain, or when
there is continued exposure of opioids. An early study in the 1950s
reported that in contrast to healthy controls and in the opioid
dependent subjects, most chronically ill patients reported the drug
as pleasant only because it reduced pain (Lasagna et al., 1955). A
later study found that opioid-dependent subjects reported more
positive effects (‘Liking’ and ‘Good drug effects’), and had lower
ratings for negative effects (‘Coasting’ and “Tired or sluggish’)
(Azolosa et al., 1994).
The rate of drug delivery to the central nervous system is widely
held to be a key predictor of the reinforcing strength of a drug.
Extensive data in non-human species suggest that rapid delivery is
associated with increased addictive potential for several recrea-
tional drugs, including opioids (Samaha and Robinson, 2005). In
humans, under well-controlled experimental settings, more rapid
infusions of opioids produced increased positive effects of the drug
in healthy volunteers (Marsch et al., 2001) as well as opioid-
dependent subjects (Comer et al., 2009). It remains unclear
whether the positive subjective reactions of rapid drug adminis-
tration are modulated in the presence of pain. Also subjective re-
actions to opioids do not themselves explain differences in self-
administration in the presence of a painful stimulus. A recent
study found that opioid use was linked to the presence of painful
stimulation in the control group but not in the drug-dependent
group even though the positive subjective effects of opioids (oxy-
codone) were similar in opioid-dependent and control groups
(Comer et al., 2010).
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Neuroimaging research has largely focussed on the analgesic
effect of opioids. There are relatively few data on the neural cor-
relates of subjective or reinforcing effects of opioids per se in
healthy drug-naïve volunteers. Several PET studies have revealed
signiﬁcant changes in regional cerebral blood ﬂow particularly in
the ACC and OFC following acute administration (single dose) of
opioids in healthy volunteers (Firestone et al., 1996). Similar activity
is observed in other MR-perfusion-based studies (Leppa et al.,
2006; Zelaya et al., 2012).
These changes might be anticipated given the distribution of
opioid receptors in the brain, and are likely neural correlates to the
subjective effects of the drug in the absence of pain (Leppa et al.,
2006; Zelaya et al., 2012).
4.4. Opioids and the brain in chronic pain
There are as yet no published data regarding how the brains of
patients with pain respond to long-term opioid therapy. The
decreased opioid receptor binding in PET studies suggest that brain
responses to opioids should differ and account for clinically rele-
vant effects (see previous section). Further support for the hy-
pothesis comes from the numerous MR-based studies that suggest
volumetric changes in the reward-circuitry in several clinical pain
populations compared to healthy controls (Schmidt-Wilcke, 2008).
However, it remains unclear whether these ﬁndings from neuro-
imaging (PET or MRI) studies relate to chronic pain or to effects
from long-term medication use (including opioids).
The issue was partly addressed in a recent longitudinal MR
study (Younger et al., 2011). Individuals with chronic low back pain
were administered oral morphine daily for 1 month, and compared
to those who used placebo. Signiﬁcant volumetric differences were
observed in several regions, including the amygdala, and anterior
cingulate cortex between patients who were treated with opioids
compared to those who received placebo. However, patients who
were treated with morphine reported signiﬁcant reduction of re-
ported pain scores, compared to those who were on placebo. Thus,
the MR ﬁndings may relate to pain relief in general, rather than to
the effects of opioid speciﬁcally. Interestingly, the volumetric
changes in themorphine group persisted for months after cessation
of opioids but no data regarding pain at that stage were reported.
It is still unclear whether structural changes in the limbic system
determine the subjective effects of exogenous opioids. A recent
FMRI study explored activity in the NA in patients with chronic
back pain (Baliki et al., 2010). This limbic structure forms part of the
mesostriatal dopamine pathway of the reward-circuitry. It encodes
information that helps determine motivation and hence the
behavioural response to external stimuli (Leknes and Tracey, 2008).
In that study, noxious heat stimulation engendered NA responses in
patients with chronic pain that were diametrically opposite to
those of controls suggesting differences in motivational value
assigned to the experimental stimulus. Whether these ﬁndings
generalise to other salient stimuli, or inﬂuence the reinforcing ef-
fects of exogenous opioids await further investigation.
5. Future directions
The goals of healthcare are to improve comfort, psychosocial
function, and longevity. Pain relief or comfort from opioid therapy
does not necessarily lead to improvements in other aspects of
health. Adverse effects can lead to signiﬁcant physical deterioration
and unintended respiratory depression and death can occur when
opioid therapy is poorly monitored (Braden et al., 2010; Webster
et al., 2011). Tolerance and opioid-induced hyperalgesia furtherlimits the effectiveness of opioid-based analgesia in patients. Cur-
rent animal data do show that tolerance and hyperalgesia are slow
to develop in the presence of overt pathology that induces pain.
However, the direct relevance of these mechanistic data for clinical
practice remains to be established. Consequently, caution is being
urged when initiating or escalating opioid therapy in patients for
pain that is disproportionate to the disease process, or in the pain
syndromes where pathology cannot as yet be demonstrated (Ngian
et al., 2011). Addictive potential is now cited as a concern when
opioids are used for treating chronic non-malignant pain (Dhalla
et al., 2011; Okie, 2010). However, deﬁning or diagnosing opioid
misuse in patients with pain remains perplexing (Weissman and
Haddox, 1989) and currently relies on behaviour that is also
observed when pain is poorly treated (Bell and Salmon, 2009).
Physicians are expected to distinguish between the use of opioids
as ‘medications to relieve pain’, and the illegitimate use of opioids
as ‘drugs to get high’(Fields, 2011). Unfortunately, there is no
objective tool that can clarify motivation for opioid use in patients
with pain. Opioids are intrinsically rewarding, but so is pain relief
(Leknes et al., 2011) achieved through its use. Disambiguating these
effects in patients with pain can be challenging. In-vivo human
neuroimaging studies of opioid pharmacology now exist, but most
data pertain to single dose opioids in healthy volunteers. There is a
clear need for studies that are relevant to the complex issues cli-
nicians face in prescribing long-term opioids for analgesia (Bruehl
et al., 2013).
References
Adler, L.J., Gyulai, F.E., Diehl, D.J., Mintun, M.A., Winter, P.M., Firestone, L.L., 1997.
Regional brain activity changes associated with fentanyl analgesia elucidated by
positron emission tomography. Anesth. Analg. 84, 120e126.
Angst, M.S., Clark, J.D., 2006. Opioid-induced hyperalgesia: a qualitative systematic
review. Anesthesiology 104, 570e587.
Angst, M.S., Koppert, W., Pahl, I., Clark, D.J., Schmelz, M., 2003. Short-term infusion
of the mu-opioid agonist remifentanil in humans causes hyperalgesia during
withdrawal. Pain 106, 49e57.
Anissian, L., Schwartz, H.W., Vincent, K., Vincent, H.K., Carpenito, J., Stambler, N.,
Ramakrishna, T., 2012. Subcutaneous methylnaltrexone for treatment of acute
opioid-induced constipation: phase 2 study in rehabilitation after orthopedic
surgery. J. Hosp. Med. 7, 67e72.
Apkarian, A.V., Bushnell, M.C., Treede, R.D., Zubieta, J.K., 2005. Human brain
mechanisms of pain perception and regulation in health and disease. Eur. J. Pain
9, 463e484.
Atlas, L.Y., Whittington, R.A., Lindquist, M.A., Wielgosz, J., Sonty, N., Wager, T.D.,
2012. Dissociable inﬂuences of opiates and expectations on pain. J. Neurosci. 32,
8053e8064.
Azolosa, J.L., Stitzer, M.L., Greenwald, M.K., 1994. Opioid physical dependence
development: effects of single versus repeated morphine pretreatments and of
subjects’ opioid exposure history. Psychopharmacology (Berl) 114, 71e80.
Baliki, M.N., Geha, P.Y., Fields, H.L., Apkarian, A.V., 2010. Predicting value of pain and
analgesia: nucleus accumbens response to noxious stimuli changes in the
presence of chronic pain. Neuron 66, 149e160.
Bannister, K., Dickenson, A.H., 2010. Opioid hyperalgesia. Curr. Opin. Support.
Palliat. Care 4, 1e5.
Baron, M.J., McDonald, P.W., 2006. Signiﬁcant pain reduction in chronic pain pa-
tients after detoxiﬁcation from high-dose opioids. J. Opioid Manag. 2, 277e282.
Becerra, L., Breiter, H.C., Wise, R., Gonzalez, R.G., Borsook, D., 2001. Reward circuitry
activation by noxious thermal stimuli. Neuron 32, 927e946.
Bell, K., Salmon, A., 2009. Pain, physical dependence and pseudoaddiction: rede-
ﬁning addiction for ’nice’ people? Int. J. Drug Policy 20, 170e178.
Bencherif, B., Fuchs, P.N., Sheth, R., Dannals, R.F., Campbell, J.N., Frost, J.J., 2002. Pain
activation of human supraspinal opioid pathways as demonstrated by [11C]-
carfentanil and positron emission tomography (PET). Pain 99, 589e598.
Bingel, U., Wanigasekera, V., Wiech, K., Ni Mhuircheartaigh, R., Lee, M.C., Ploner, M.,
Tracey, I., 2011. The effect of treatment expectation on drug efﬁcacy: imaging
the analgesic beneﬁt of the opioid remifentanil. Sci. Transl. Med. 3, 70ra14.
Braden, J.B., Russo, J., Fan, M.Y., Edlund, M.J., Martin, B.C., DeVries, A., Sullivan, M.D.,
2010. Emergency department visits among recipients of chronic opioid therapy.
Arch. Intern. Med. 170, 1425e1432.
British, 2010. Opioids for Persistent Pain: Good Practice. British Pain Society.
Bruehl, S., Apkarian, A.V., Ballantyne, J.C., Berger, A., Borsook, D., Chen, W.G.,
Farrar, J.T., Haythornthwaite, J.A., Horn, S.D., Iadarola, M.J., Inturrisi, C.E., Lao, L.,
Mackey, S., Mao, J., Sawczuk, A., Uhl, G.R., Witter, J., Woolf, C.J., Zubieta, J.K.,
Lin, Y., 2013. Personalized medicine and opioid analgesic prescribing for chronic
pain: opportunities and challenges. J. Pain 14, 103e113.
M.C. Lee et al. / Neuropharmacology 84 (2014) 123e130 129Celerier, E., Gonzalez, J.R., Maldonado, R., Cabanero, D., Puig, M.M., 2006. Opioid-
induced hyperalgesia in a murine model of postoperative pain: role of nitric
oxide generated from the inducible nitric oxide synthase. Anesthesiology 104,
546e555.
Chen, L., Malarick, C., Seefeld, L., Wang, S., Houghton, M., Mao, J., 2009. Altered
quantitative sensory testing outcome in subjects with opioid therapy. Pain 143,
65e70.
Chou, R., Ballantyne, J.C., Fanciullo, G.J., Fine, P.G., Miaskowski, C., 2009a. Research
gaps on use of opioids for chronic noncancer pain: ﬁndings from a review of the
evidence for an American Pain Society and American Academy of Pain Medicine
clinical practice guideline. J. Pain 10, 147e159.
Chou, R., Fanciullo, G.J., Fine, P.G., Adler, J.A., Ballantyne, J.C., Davies, P.,
Donovan, M.I., Fishbain, D.A., Foley, K.M., Fudin, J., Gilson, A.M., Kelter, A.,
Mauskop, A., O’Connor, P.G., Passik, S.D., Pasternak, G.W., Portenoy, R.K.,
Rich, B.A., Roberts, R.G., Todd, K.H., Miaskowski, C., 2009b. Clinical guidelines
for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10,
113e130.
Chu, L.F., Clark, D.J., Angst, M.S., 2006. Opioid tolerance and hyperalgesia in chronic
pain patients after one month of oral morphine therapy: a preliminary pro-
spective study. J. Pain 7, 43e48.
Colpaert, F.C., Meert, T., De Witte, P., Schmitt, P., 1982. Further evidence validating
adjuvant arthritis as an experimental model of chronic pain in the rat. Life Sci.
31, 67e75.
Colpaert, F.C., Tarayre, J.P., Alliaga, M., Bruins Slot, L.A., Attal, N., Koek, W., 2001.
Opiate self-administration as a measure of chronic nociceptive pain in arthritic
rats. Pain 91, 33e45.
Comer, S.D., Ashworth, J.B., Sullivan, M.A., Vosburg, S.K., Saccone, P.A., Foltin, R.W.,
2009. Relationship between rate of infusion and reinforcing strength of oxy-
codone in humans. J. Opioid Manag. 5, 203e212.
Comer, S.D., Sullivan, M.A., Vosburg, S.K., Kowalczyk, W.J., Houser, J., 2010. Abuse
liability of oxycodone as a function of pain and drug use history. Drug Alcohol
Depend. 109, 130e138.
Compton, P., Charuvastra, V.C., Kintaudi, K., Ling, W., 2000. Pain responses in
methadone-maintained opioid abusers. J. Pain Symptom Manag. 20, 237e245.
Conley, K.M., Toledano, A.Y., Apfelbaum, J.L., Zacny, J.P., 1997. Modulating effects of a
cold water stimulus on opioid effects in volunteers. Psychopharmacology (Berl)
131, 313e320.
Cooper, Z.D., Sullivan, M.A., Vosburg, S.K., Manubay, J.M., Haney, M., Foltin, R.W.,
Evans, S.M., Kowalczyk, W.J., Saccone, P.A., Comer, S.D., 2012 Jun. Effects of
repeated oxycodone administration on its analgesic and subjective effects in
normal, healthy volunteers. Behav. Pharmacol. 23 (3), 271e279.
Cortinez, L.I., Brandes, V., Munoz, H.R., Guerrero, M.E., Mur, M., 2001. No clinical
evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br. J.
Anaesth. 87, 866e869.
Craig, A.D., 2003. A new view of pain as a homeostatic emotion. Trends Neurosci.
26, 303e307.
Craig, A.D., 2009. How do you feelenow? The anterior insula and human aware-
ness. Nat. Rev. Neurosci. 10, 59e70.
Dhalla, I.A., Persaud, N., Juurlink, D.N., 2011. Facing up to the prescription opioid
crisis. BMJ 343, d5142.
Dickenson, A.H., Kieffer, B.L., 2013. Opioids: basic mechanisms. In: McMahon, S.,
Koltzenburg, M., Tracey, I., Turk, D.C. (Eds.), Textbook of Pain. Elsevier, Phila-
delphia, PA.
Doverty, M., White, J.M., Somogyi, A.A., Bochner, F., Ali, R., Ling, W., 2001. Hyper-
algesic responses in methadone maintenance patients. Pain 90, 91e96.
Eippert, F., Finsterbusch, J., Bingel, U., Buchel, C., 2009. Direct evidence for spinal
cord involvement in placebo analgesia. Science 326, 404.
Ewan, E.E., Martin, T.J., 2011. Opioid facilitation of rewarding electrical brain
stimulation is suppressed in rats with neuropathic pain. Anesthesiology 114,
624e632.
Ewan, E.E., Martin, T.J., 2012. Intracranial self-stimulation of the paraventricular
nucleus of the hypothalamus: increased facilitation by morphine compared to
cocaine. Anesthesiology 116, 1116e1123.
Fields, H.L., 2011. The doctor’s dilemma: opiate analgesics and chronic pain. Neuron
69, 591e594.
Firestone, L.L., Gyulai, F., Mintun, M., Adler, L.J., Urso, K., Winter, P.M., 1996. Human
brain activity response to fentanyl imaged by positron emission tomography.
Anesth. Analg. 82, 1247e1251.
Fishbain, D.A., Cole, B., Lewis, J.E., Gao, J., Rosomoff, R.S., 2009. Do opioids induce
hyperalgesia in humans? An evidence-based structured review. Pain Med. 10,
829e839.
Gardner, E.L., 2000. What we have learned about addiction from animal models of
drug self-administration. Am. J. Addict. 9, 285e313.
Guignard, B., Bossard, A.E., Coste, C., Sessler, D.I., Lebrault, C., Alfonsi, P., Fletcher, D.,
Chauvin, M., 2000. Acute opioid tolerance: intraoperative remifentanil in-
creases postoperative pain and morphine requirement. Anesthesiology 93,
409e417.
Harris, R.E., Clauw, D.J., Scott, D.J., McLean, S.A., Gracely, R.H., Zubieta, J.K., 2007.
Decreased central mu-opioid receptor availability in ﬁbromyalgia. J. Neurosci.
27, 10000e10006.
Heinl, C., Drdla-Schutting, R., Xanthos, D.N., Sandkuhler, J., 2011. Distinct
mechanisms underlying pronociceptive effects of opioids. J. Neurosci. 31,
16748e16756.
Henriksen, G., Willoch, F., 2008. Imaging of opioid receptors in the central nervous
system. Brain 131, 1171e1196.IASP, 1994. Part III: pain terms, a current list with deﬁnitions and notes on usage. In:
Merskey, M., Bogduk, N. (Eds.), Classiﬁcation of Chronic Pain. Descriptions of
Chronic Pain Syndromes and Deﬁnitions of Pain Terms. IASP Press, Seattle,
pp. 209e214.
Iwai, S., Kiguchi, N., Kobayashi, Y., Fukazawa, Y., Saika, F., Ueno, K., Yamamoto, C.,
Kishioka, S., 2012. Inhibition of morphine tolerance is mediated by painful
stimuli via central mechanisms. Drug Discov. Ther. 6, 31e37.
Jensen, K.B., Lonsdorf, T.B., Schalling, M., Kosek, E., Ingvar, M., 2009. Increased
sensitivity to thermal pain following a single opiate dose is inﬂuenced by the
COMT val(158)met polymorphism. PLoS One 4, e6016.
Jones, A.K., Cunningham, V.J., Ha-Kawa, S., Fujiwara, T., Luthra, S.K., Silva, S.,
Derbyshire, S., Jones, T., 1994. Changes in central opioid receptor binding in
relation to inﬂammation and pain in patients with rheumatoid arthritis. Br. J.
Rheumatol. 33, 909e916.
Jones, A.K., Watabe, H., Cunningham, V.J., Jones, T., 2004. Cerebral decreases in
opioid receptor binding in patients with central neuropathic pain measured by
[11C]diprenorphine binding and PET. Eur. J. Pain 8, 479e485.
Kahan, M., Mailis-Gagnon, A., Wilson, L., Srivastava, A., 2011a. Canadian guideline
for safe and effective use of opioids for chronic noncancer pain: clinical sum-
mary for family physicians. Part 1: general population. Can. Fam. Physician 57,
1257e1266, e1407e1218.
Kahan, M., Wilson, L., Mailis-Gagnon, A., Srivastava, A., 2011b. Canadian guideline
for safe and effective use of opioids for chronic noncancer pain: clinical sum-
mary for family physicians. Part 2: special populations. Can. Fam. Physician 57,
1269e1276, e1419e1228.
Kendall, S.E., Sjogren, P., Pimenta, C.A., Hojsted, J., Kurita, G.P., 2010. The cognitive
effects of opioids in chronic non-cancer pain. Pain 150, 225e230.
King, T., Vardanyan, A., Majuta, L., Melemedjian, O., Nagle, R., Cress, A.E.,
Vanderah, T.W., Lai, J., Porreca, F., 2007. Morphine treatment accelerates
sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine
model of bone cancer. Pain 132, 154e168.
Klega, A., Eberle, T., Buchholz, H.G., Maus, S., Maihofner, C., Schreckenberger, M.,
Birklein, F., 2010. Central opioidergic neurotransmission in complex regional
pain syndrome. Neurology 75, 129e136.
Lasagna, L., Von Felsinger, J.M., Beecher, H.K., 1955. Drug-induced mood changes in
man. I. Observations on healthy subjects, chronically ill patients, and post-
addicts. J. Am. Med. Assoc. 157, 1006e1020.
Lee, L.H., Irwin, M.G., Lui, S.K., 2005. Intraoperative remifentanil infusion does not
increase postoperative opioid consumption compared with 70% nitrous oxide.
Anesthesiology 102, 398e402.
Leknes, S., Lee, M., Berna, C., Andersson, J., Tracey, I., 2011. Relief as a reward: he-
donic and neural responses to safety from pain. PLoS One 6, e17870.
Leknes, S., Tracey, I., 2008. A common neurobiology for pain and pleasure. Nat. Rev.
Neurosci. 9, 314e320.
Leppa, M., Korvenoja, A., Carlson, S., Timonen, P., Martinkauppi, S., Ahonen, J.,
Rosenberg, P.H., Aronen, H.J., Kalso, E., 2006. Acute opioid effects on human brain
as revealed by functional magnetic resonance imaging. Neuroimage 31, 661e669.
Li, X., Angst, M.S., Clark, J.D., 2001. Opioid-induced hyperalgesia and incisional pain.
Anesth. Analg. 93, 204e209.
Liang, D., Shi, X., Qiao, Y., Angst, M.S., Yeomans, D.C., Clark, J.D., 2008. Chronic
morphine administration enhances nociceptive sensitivity and local cytokine
production after incision. Mol. Pain 4, 7.
Luginbuhl, M., Gerber, A., Schnider, T.W., Petersen-Felix, S., Arendt-Nielsen, L.,
Curatolo, M., 2003. Modulation of remifentanil-induced analgesia, hyperalgesia,
and tolerance by small-dose ketamine in humans. Anesth. Analg. 96, 726e732
(table of contents).
Lyness, W.H., Smith, F.L., Heavner, J.E., Iacono, C.U., Garvin, R.D., 1989. Morphine
self-administration in the rat during adjuvant-induced arthritis. Life Sci. 45,
2217e2224.
Maarrawi, J., Peyron, R., Mertens, P., Costes, N., Magnin, M., Sindou, M., Laurent, B.,
Garcia-Larrea, L., 2007. Differential brain opioid receptor availability in central
and peripheral neuropathic pain. Pain 127, 183e194.
Marsch, L.A., Bickel, W.K., Badger, G.J., Rathmell, J.P., Swedberg, M.D., Jonzon, B.,
Norsten-Hoog, C., 2001. Effects of infusion rate of intravenously administered
morphine on physiological, psychomotor, and self-reported measures in
humans. J. Pharmacol. Exp. Ther. 299, 1056e1065.
Martin, M., Hurley, R.A., Taber, K.H., 2007. Is opiate addiction associated with
longstanding neurobiological changes? J. Neuropsychiatry Clin. Neurosci. 19,
242e248.
Mazzola, L., Isnard, J., Peyron, R., Guenot, M., Mauguiere, F., 2009. Somatotopic or-
ganization of pain responses to direct electrical stimulation of the human
insular cortex. Pain 146, 99e104.
Melichar, J.K., Hume, S.P., Williams, T.M., Daglish, M.R., Taylor, L.G., Ahmad, R.,
Malizia, A.L., Brooks, D.J., Myles, J.S., Lingford-Hughes, A., Nutt, D.J., 2005. Using
[11C]diprenorphine to image opioid receptor occupancy by methadone in opioid
addiction: clinical and preclinical studies. J. Pharmacol. Exp. Ther. 312, 309e315.
Michna, E., Blonsky, E.R., Schulman, S., Tzanis, E., Manley, A., Zhang, H., Iyer, S.,
Randazzo, B., 2011. Subcutaneous methylnaltrexone for treatment of opioid-
induced constipation in patients with chronic, nonmalignant pain: a random-
ized controlled study. J. Pain 12, 554e562.
Mogil, J.S., 2009. Animal models of pain: progress and challenges. Nat. Rev. Neu-
rosci. 10, 283e294.
Muscoli, C., Doyle, T., Dagostino, C., Bryant, L., Chen, Z., Watkins, L.R., Ryerse, J.,
Bieberich, E., Neumman, W., Salvemini, D., 2010. Counter-regulation of opioid
analgesia by glial-derived bioactive sphingolipids. J. Neurosci. 30, 15400e15408.
M.C. Lee et al. / Neuropharmacology 84 (2014) 123e130130Nagi, K., Pineyro, G., 2011. Regulation of opioid receptor signalling: implications for
the development of analgesic tolerance. Mol. Brain 4, 25.
Narita, M., Kishimoto, Y., Ise, Y., Yajima, Y., Misawa, K., Suzuki, T., 2005. Direct evi-
dence for the involvement of the mesolimbic kappa-opioid system in the
morphine-induced rewarding effect under an inﬂammatory pain-like state.
Neuropsychopharmacology 30, 111e118.
Ngian, G.S., Guymer, E.K., Littlejohn, G.O., 2011. The use of opioids in ﬁbromyalgia.
Int. J. Rheum. Dis. 14, 6e11.
Noble, M., Treadwell, J.R., Tregear, S.J., Coates, V.H., Wiffen, P.J., Akafomo, C.,
Schoelles, K.M., 2010. Long-term opioid management for chronic noncancer
pain. Cochrane Database Syst. Rev.. CD006605.
Oertel, B.G., Preibisch, C., Wallenhorst, T., Hummel, T., Geisslinger, G.,
Lanfermann, H., Lotsch, J., 2008. Differential opioid action on sensory and af-
fective cerebral pain processing. Clin. Pharmacol. Ther. 83, 577e588.
Okie, S., 2010. A ﬂood of opioids, a rising tide of deaths. N. Engl. J. Med. 363,
1981e1985.
Ostrowsky, K., Magnin, M., Ryvlin, P., Isnard, J., Guenot, M., Mauguiere, F., 2002.
Representation of pain and somatic sensation in the human insula: a study of
responses to direct electrical cortical stimulation. Cereb. Cortex 12, 376e385.
Ozaki, S., Narita, M., Narita, M., Iino, M., Miyoshi, K., Suzuki, T., 2003. Suppression of
the morphine-induced rewarding effect and G-protein activation in the lower
midbrain following nerve injury in the mouse: involvement of G-protein-
coupled receptor kinase 2. Neuroscience 116, 89e97.
Ozaki, S., Narita, M., Ozaki, M., Khotib, J., Suzuki, T., 2004. Role of extracellular
signal-regulated kinase in the ventral tegmental area in the suppression of the
morphine-induced rewarding effect in mice with sciatic nerve ligation.
J. Neurochem. 88, 1389e1397.
Pattinson, K.T., Rogers, R., Mayhew, S.D., Tracey, I., Wise, R.G., 2007. Pharmacological
FMRI: measuring opioid effects on the BOLD response to hypercapnia. J. Cereb.
Blood Flow Metab. 27, 414e423.
Pergolizzi Jr., J.V., Gharibo, C., Passik, S., Labhsetwar, S., Taylor Jr., R., Pergolizzi, J.S.,
Muller-Schwefe, G., 2012. Dynamic risk factors in the misuse of opioid anal-
gesics. J. Psychosom. Res. 72, 443e451.
Petersen, K.L., Jones, B., Segredo, V., Dahl, J.B., Rowbotham, M.C., 2001. Effect of
remifentanil on pain and secondary hyperalgesia associated with the heate
capsaicin sensitization model in healthy volunteers. Anesthesiology 94, 15e20.
Petrovic, P., Kalso, E., Petersson, K.M., Ingvar, M., 2002. Placebo and opioid anal-
gesiae imaging a shared neuronal network. Science 295, 1737e1740.
Ploghaus, A., Narain, C., Beckmann, C.F., Clare, S., Bantick, S., Wise, R.,
Matthews, P.M., Rawlins, J.N., Tracey, I., 2001. Exacerbation of pain by anxiety is
associated with activity in a hippocampal network. J. Neurosci. 21, 9896e9903.
Ploner, M., Lee, M.C., Wiech, K., Bingel, U., Tracey, I., 2010. Prestimulus functional
connectivity determines pain perception in humans. Proc. Natl. Acad. Sci. U. S.
A. 107, 355e360.
Portenoy, R.K., 2011. Treatment of cancer pain. Lancet 377, 2236e2247.
Pud, D., Cohen, D., Lawental, E., Eisenberg, E., 2006. Opioids and abnormal pain
perception: new evidence from a study of chronic opioid addicts and healthy
subjects. Drug Alcohol Depend. 82, 218e223.
Rabiner, E.A., Beaver, J., Makwana, A., Searle, G., Long, C., Nathan, P.J.,
Newbould, R.D., Howard, J., Miller, S.R., Bush, M.A., Hill, S., Reiley, R., Passchier, J.,
Gunn, R.N., Matthews, P.M., Bullmore, E.T., 2011. Molecular and functional
neuroimaging of human opioid receptor pharmacology. Mol. Psychiatry 16, 785.
Raghavendra, V., Rutkowski, M.D., DeLeo, J.A., 2002. The role of spinal neuro-
immune activation in morphine tolerance/hyperalgesia in neuropathic and
sham-operated rats. J. Neurosci. 22, 9980e9989.
Rauf, K., Vohra, A., Fernandez-Jimenez, P., O’Keeffe, N., Forrest, M., 2005. Remi-
fentanil infusion in association with fentanyl-propofol anaesthesia in patients
undergoing cardiac surgery: effects on morphine requirement and post-
operative analgesia. Br. J. Anaesth. 95, 611e615.
Reznikov, I., Pud, D., Eisenberg, E., 2005. Oral opioid administration and hyper-
algesia in patients with cancer or chronic nonmalignant pain. Br. J. Clin. Phar-
macol. 60, 311e318.
Rivat, C., Vera-Portocarrero, L.P., Ibrahim, M.M., Mata, H.P., Stagg, N.J., De Felice, M.,
Porreca, F., Malan, T.P., 2009. Spinal NK-1 receptor-expressing neurons and
descending pathways support fentanyl-induced pain hypersensitivity in a rat
model of postoperative pain. Eur. J. Neurosci. 29, 727e737.
Samaha, A.N., Robinson, T.E., 2005. Why does the rapid delivery of drugs to the
brain promote addiction? Trends Pharmacol. Sci. 26, 82e87.
Schmidt-Wilcke, T., 2008. Variations in brain volume and regional morphology
associated with chronic pain. Curr. Rheumatol. Rep. 10, 467e474.
Scott, D.J., Stohler, C.S., Egnatuk, C.M., Wang, H., Koeppe, R.A., Zubieta, J.K., 2008.
Placebo and nocebo effects are deﬁned by opposite opioid and dopaminergic
responses. Arch. Gen. Psychiatry 65, 220e231.
Seymour, B., O’Doherty, J.P., Koltzenburg, M., Wiech, K., Frackowiak, R., Friston, K.,
Dolan, R., 2005. Opponent appetitive-aversive neural processes underlie pre-
dictive learning of pain relief. Nat. Neurosci. 8, 1234e1240.
Simonnet, G., Rivat, C., 2003. Opioid-induced hyperalgesia: abnormal or normal
pain? Neuroreport 14, 1e7.
Sprenger, T., Valet, M., Boecker, H., Henriksen, G., Spilker, M.E., Willoch, F.,
Wagner, K.J., Wester, H.J., Tolle, T.R., 2006. Opioidergic activation in the medial
pain system after heat pain. Pain 122, 63e67.Thomas, J., Karver, S., Cooney, G.A., Chamberlain, B.H., Watt, C.K., Slatkin, N.E.,
Stambler, N., Kremer, A.B., Israel, R.J., 2008. Methylnaltrexone for opioid-
induced constipation in advanced illness. N. Engl. J. Med. 358, 2332e2343.
Tompkins, D.A., Campbell, C.M., 2011. Opioid-induced hyperalgesia: clinically
relevant or extraneous research phenomenon? Curr. Pain Headache Rep. 15,
129e136.
Tracey, I., 2005. Nociceptive processing in the human brain. Curr. Opin. Neurobiol.
15, 478e487.
Tracey, I., 2010 Nov. Getting the pain you expect: mechanisms of placebo, nocebo
and reappraisal effects in humans. Nat. Med. 16 (11), 1277e1283.
Tracey, I., Mantyh, P.W., 2007. The cerebral signature for pain perception and its
modulation. Neuron 55, 377e391.
Urch, C.E., Donovan-Rodriguez, T., Gordon-Williams, R., Bee, L.A., Dickenson, A.H.,
2005. Efﬁcacy of chronic morphine in a rat model of cancer-induced bone pain:
behavior and in dorsal horn pathophysiology. J. Pain 6, 837e845.
Vaccarino, A.L., Marek, P., Kest, B., Ben-Eliyahu, S., Couret Jr., L.C., Kao, B.,
Liebeskind, J.C., 1993. Morphine fails to produce tolerance when administered
in the presence of formalin pain in rats. Brain Res. 627, 287e290.
van Dorp, E.L., Kest, B., Kowalczyk, W.J., Morariu, A.M., Waxman, A.R., Arout, C.A.,
Dahan, A., Sarton, E.Y., 2009. Morphine-6beta-glucuronide rapidly increases
pain sensitivity independently of opioid receptor activity in mice and humans.
Anesthesiology 110, 1356e1363.
Wager, T.D., Scott, D.J., Zubieta, J.K., 2007. Placebo effects on human mu-opioid
activity during pain. Proc. Natl. Acad. Sci. U. S. A. 104, 11056e11061.
Wagner, K.J., Sprenger, T., Kochs, E.F., Tolle, T.R., Valet, M., Willoch, F., 2007. Imaging
human cerebral pain modulation by dose-dependent opioid analgesia: a posi-
tron emission tomography activation study using remifentanil. Anesthesiology
106, 548e556.
Wanigasekera, V., Lee, M.C., Rogers, R., Hu, P., Tracey, I., 2011. Neural correlates of an
injury-free model of central sensitization induced by opioid withdrawal in
humans. J. Neurosci. 31, 2835e2842.
Wanigasekera, V., Lee, M.C., Rogers, R., Kong, Y., Leknes, S., Andersson, J., Tracey, I.,
2012. Baseline reward circuitry activity and trait reward responsiveness predict
expression of opioid analgesia in healthy subjects. Proc. Natl. Acad. Sci. U. S. A.
109, 17705e17710.
Waxman, A.R., Arout, C., Caldwell, M., Dahan, A., Kest, B., 2009. Acute and chronic
fentanyl administration causes hyperalgesia independently of opioid receptor
activity in mice. Neurosci. Lett. 462, 68e72.
Webster, L.R., Cochella, S., Dasgupta, N., Fakata, K.L., Fine, P.G., Fishman, S.M.,
Grey, T., Johnson, E.M., Lee, L.K., Passik, S.D., Peppin, J., Porucznik, C.A., Ray, A.,
Schnoll, S.H., Stieg, R.L., Wakeland, W., 2011. An analysis of the root causes for
opioid-related overdose deaths in the United States. Pain Med. 12 (Suppl. 2),
S26eS35.
Weeks, J.R., 1962. Experimental morphine addiction: method for automatic intra-
venous injections in unrestrained rats. Science 138, 143e144.
Weissman, D.E., Haddox, J.D., 1989. Opioid pseudoaddiction e an iatrogenic syn-
drome. Pain 36, 363e366.
Willoch, F., Schindler, F., Wester, H.J., Empl, M., Straube, A., Schwaiger, M., Conrad, B.,
Tolle, T.R., 2004. Central poststroke pain and reduced opioid receptor binding
within pain processing circuitries: a [11C]diprenorphine PET study. Pain 108,
213e220.
Wise, R.G., Rogers, R., Painter, D., Bantick, S., Ploghaus, A., Williams, P., Rapeport, G.,
Tracey, I., 2002. Combining fMRI with a pharmacokinetic model to determine
which brain areas activated by painful stimulation are speciﬁcally modulated by
remifentanil. Neuroimage 16, 999e1014.
Wise, R.G., Tracey, I., 2006. The role of fMRI in drug discovery. J. Magn. Reson.
Imaging 23, 862e876.
Wise, R.G., Williams, P., Tracey, I., 2004. Using fMRI to quantify the time dependence
of remifentanil analgesia in the human brain. Neuropsychopharmacology 29,
626e635.
Wu, C.L., Raja, S.N., 2011. Treatment of acute postoperative pain. Lancet 377, 2215e
2225.
Younger, J.W., Chu, L.F., D’Arcy, N.T., Trott, K.E., Jastrzab, L.E., Mackey, S.C., 2011.
Prescription opioid analgesics rapidly change the human brain. Pain 152,
1803e1810.
Zacny, J.P., McKay, M.A., Toledano, A.Y., Marks, S., Young, C.J., Klock, P.A.,
Apfelbaum, J.L., 1996. The effects of a cold-water immersion stressor on the
reinforcing and subjective effects of fentanyl in healthy volunteers. Drug
Alcohol Depend. 42, 133e142.
Zelaya, F.O., Zois, E., Muller-Pollard, C., Lythgoe, D.J., Lee, S., Andrews, C., Smart, T.,
Conrod, P., Vennart, W., Williams, S.C., Mehta, M.A., Reed, L.J., 2012. The
response to rapid infusion of fentanyl in the human brain measured using
pulsed arterial spin labelling. MAGMA 25, 163e175.
Zollner, C., Mousa, S.A., Fischer, O., Rittner, H.L., Shaqura, M., Brack, A., Shakibaei, M.,
Binder, W., Urban, F., Stein, C., Schafer, M., 2008. Chronic morphine use does not
induce peripheral tolerance in a rat model of inﬂammatory pain. J. Clin. Invest.
118, 1065e1073.
Zubieta, J.K., Smith, Y.R., Bueller, J.A., Xu, Y., Kilbourn, M.R., Jewett, D.M., Meyer, C.R.,
Koeppe, R.A., Stohler, C.S., 2001. Regional mu opioid receptor regulation of
sensory and affective dimensions of pain. Science 293, 311e315.
